scholarly journals Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria

2013 ◽  
Vol 41 (7) ◽  
pp. 1347-1366 ◽  
Author(s):  
Joe Bentz ◽  
Michael P. O’Connor ◽  
Dallas Bednarczyk ◽  
JoAnn Coleman ◽  
Caroline Lee ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Drug Interaction ◽  
Decision Criteria ◽  
Inhibitory Potency ◽  
Experimental Systems ◽  
P Glycoprotein ◽  
Drug Drug Interaction

In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug–drug interaction with methotrexate

2011 ◽  
Vol 43 (1-2) ◽  
pp. 41-49 ◽  
Author(s):  
Robert Elsby ◽  
Lisa Fox ◽  
David Stresser ◽  
Mark Layton ◽  
Caroline Butters ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Drug Interaction ◽  
Drug Drug Interaction

In Vitro Predictability of Drug-Drug Interaction Likelihood of P-Glycoprotein-Mediated Efflux of Dabigatran Etexilate Based on [I]2/IC50 Threshold

2013 ◽  
Vol 42 (2) ◽  
pp. 257-263 ◽  
Author(s):  
Wataru Kishimoto ◽  
Naoki Ishiguro ◽  
Eva Ludwig-Schwellinger ◽  
Thomas Ebner ◽  
Olaf Schaefer
Keyword(s):  
Drug Interaction ◽  
Dabigatran Etexilate ◽  
P Glycoprotein ◽  
Drug Drug Interaction

Recommendations for in vitro CYP3A4 mRNA data analysis for drug-drug interaction risk assessment from the IQ Induction working group

2019 ◽  
Vol 34 (1) ◽  
pp. S44
Author(s):  
Donald Tweedie ◽  
Jane R. Kenny ◽  
Diane Ramsden ◽  
David Buckley ◽  
Shannon Dallas ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Drug Interaction ◽  
Data Analysis ◽  
Working Group ◽  
Drug Drug Interaction
Sign in / Sign up

Export Citation Format

Share Document